ES2631137A1 - Use of an aqueous composition comprising nacl, aloe and chamomile for the treatment and/or prevention of nasal congestion (Machine-translation by Google Translate, not legally binding) - Google Patents

Use of an aqueous composition comprising nacl, aloe and chamomile for the treatment and/or prevention of nasal congestion (Machine-translation by Google Translate, not legally binding) Download PDF

Info

Publication number
ES2631137A1
ES2631137A1 ES201531879A ES201531879A ES2631137A1 ES 2631137 A1 ES2631137 A1 ES 2631137A1 ES 201531879 A ES201531879 A ES 201531879A ES 201531879 A ES201531879 A ES 201531879A ES 2631137 A1 ES2631137 A1 ES 2631137A1
Authority
ES
Spain
Prior art keywords
weight
composition
use according
nasal
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201531879A
Other languages
Spanish (es)
Other versions
ES2631137B1 (en
Inventor
Aurora Del Carmen GARRE CONTRERAS
Saioa AZKOITI IBÁÑEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Cinfa SA
Original Assignee
Laboratorios Cinfa SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cinfa SA filed Critical Laboratorios Cinfa SA
Priority to ES201531879A priority Critical patent/ES2631137B1/en
Publication of ES2631137A1 publication Critical patent/ES2631137A1/en
Application granted granted Critical
Publication of ES2631137B1 publication Critical patent/ES2631137B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Use of an aqueous composition comprising nacl, aloe and chamomile for the treatment and/or prevention of nasal congestion. The present invention provides the use of an aqueous composition comprising: (I) from 0.5 to 3% by weight of nacl, (II) from 0.1 to 1% by weight of aloe vera extract, and (III) from 0.5 to 5% by weight of chamomile extract, for the preparation of a medicament for the prevention and/or treatment of nasal congestion. The compositions may also contain mint. The invention also provides the compositions described above for nasal lavage. (Machine-translation by Google Translate, not legally binding)

Description

55

1010

15fifteen

20twenty

2525

3030

3535

DESCRIPCIONDESCRIPTION

Uso de una composition acuosa que comprende NaCI, Aloe y manzanilla para el tratamiento y/o prevention de la congestion nasalUse of an aqueous composition comprising NaCI, Aloe and chamomile for the treatment and / or prevention of nasal congestion

La presente invention se refiere al campo de los productos sanitarios para higiene nasal, prevencion y tratamiento de la congestion nasal. Mas concretamente se refiere a nuevas composiciones con efecto descongestivo.The present invention relates to the field of sanitary products for nasal hygiene, prevention and treatment of nasal congestion. More specifically, it refers to new compositions with decongestant effect.

ESTADO DE LA TECNICASTATE OF THE TECHNIQUE

La nariz constituye la puerta de entrada del aire al tracto respiratorio superior. La mucosa nasal (parte interna de la nariz) filtra el aire inspirado con el fin de eliminar el polvo, los germenes y cualquier particula irritante que pueda contener. Posteriormente, lo calienta y humedece para evitar que los pulmones y los tubos que conducen a ellos se resequen. Ademas la nariz contribuye al olfato y al gusto. En ocasiones, las modificaciones de las condiciones atmosfericas (temperatura y presion) asi como la exposition a agentes infecciosos, irritantes y alergenos produce una respuesta inflamatoria en la mucosa de las fosas y los senos nasales. Cuando esta inflamacion se produce da origen a la rinosinusitis. La rinosinusitis se caracteriza por una hipersecrecion de moco y obstruccion nasal (congestion o rinorrea), lo que dificulta la respiracion provocando gran incomodidad y complicaciones como dolores de cabeza y de oidos. La persistencia de la congestion nasal puede, ademas favorecer la infection por patogenos desembocando en bronquitis, otitis o incluso neumoma.The nose constitutes the entrance door of the air to the upper respiratory tract. The nasal mucosa (inner part of the nose) filters the inspired air in order to eliminate dust, germs and any irritating particles it may contain. Subsequently, it heats and moistens to prevent the lungs and the tubes that lead to them from drying out. Also the nose contributes to smell and taste. Occasionally, changes in atmospheric conditions (temperature and pressure) as well as exposure to infectious agents, irritants and allergens produces an inflammatory response in the mucosa of the nostrils and sinuses. When this inflammation occurs it gives rise to rhinosinusitis. Rhinosinusitis is characterized by a hypersecretion of mucus and nasal obstruction (congestion or rhinorrhea), which makes breathing difficult causing great discomfort and complications such as headaches and ears. The persistence of nasal congestion may also favor infection by pathogens leading to bronchitis, otitis or even pneumoma.

Una adecuada limpieza nasal es beneficiosa para liberar las cavidades nasales de particulas contaminantes, virus, bacterias y otras impurezas que pueden provocar la inflamacion de la mucosa, previniendo asi la congestion nasal y sus complicaciones. Cuando la congestion ya es evidente, conviene eliminarla mediante un tratamiento indicado. En este sentido se han propuesto varios medicamentos para el tratamiento de los conductos nasales. En general, estos medicamentos contienen un estimulante alfa o vasoconstrictor como la efedrina, NeoSynephrine (clorhidrato de fenilefrina) o Afrin (clorhidrato de oximetazolina) pueden ser utilizados como un descongestiva. Pero dichos medicamentos tienen varios posibles efectos secundarios, como atrofia de las mucosas nasales, aumento de la presion arterial, irregularidades cardiacas y efectoProper nasal cleaning is beneficial to free the nasal cavities of contaminating particles, viruses, bacteria and other impurities that can cause inflammation of the mucosa, thus preventing nasal congestion and its complications. When congestion is already evident, it should be eliminated by an indicated treatment. In this regard, several medications have been proposed for the treatment of nasal passages. In general, these medications contain an alpha stimulant or vasoconstrictor such as ephedrine, NeoSynephrine (phenylephrine hydrochloride) or Afrin (oxymetazoline hydrochloride) can be used as a decongestant. But such medications have several possible side effects, such as atrophy of the nasal mucous membranes, increased blood pressure, cardiac irregularities and effect

55

1010

15fifteen

20twenty

2525

3030

3535

rebote, por lo que el uso prolongado no es generalmente aconsejado. Otro tratamiento consiste en la administration local de preparaciones que contienen aceites esenciales y/o derivados aromaticos terpenicos. Su action descongestiva local, sin embargo, no esta cientificamente bien establecida y su uso, solos o en combination, puede llegar a ser peligroso para la salud por el riesgo de causar irritaciones locales o problemas del sistema nervioso central. Este riesgo aumenta cuando estas preparaciones contienen alcohol, incluso en bajas proporciones, o sustancias antisepticas que pueden ser irritantes para las membranas mucosas nasales. Los bebes, ninos pequenos o personas de edad avanzada estan particularmente expuestos a todos estos riesgosrebound, so prolonged use is not generally advised. Another treatment consists in the local administration of preparations containing essential oils and / or aromatic terpenic derivatives. Its local decongestant action, however, is not scientifically well established and its use, alone or in combination, can become dangerous to health due to the risk of causing local irritations or problems of the central nervous system. This risk increases when these preparations contain alcohol, even in low proportions, or antiseptic substances that can be irritating to nasal mucous membranes. Babies, young children or the elderly are particularly exposed to all these risks

Por otro lado, el agua de mar se ha utilizado tradicionalmente para enjuagar el conducto nasal, como parte de un tratamiento para problemas de rinosinusitis. Pero el agua de mar por si sola carece de efecto descongestivo y su uso en la limpieza o irrigation nasal esta, ademas, asociada a un malestar significativo.On the other hand, seawater has traditionally been used to rinse the nasal passage, as part of a treatment for rhinosinusitis problems. But sea water alone has no decongestant effect and its use in nasal cleaning or irrigation is also associated with significant discomfort.

En vista de todo lo anterior, es evidente que se hace necesario proporcionar nuevas estrategias para la correcta higiene nasal, asi como para prevenir y curar la congestion nasal, que no adolezcan de las desventajas mencionadas.In view of the above, it is clear that it is necessary to provide new strategies for proper nasal hygiene, as well as to prevent and cure nasal congestion, which does not suffer from the aforementioned disadvantages.

EXPLICACION DE LA INVENCIONEXPLANATION OF THE INVENTION

Los inventores han disenado nuevas composiciones descongestivas que presentan ventajas en terminos de efectividad y comodidad, a la vez que no presentan efectos secundarios perjudiciales. Estas composiciones comprenden ingredientes naturales, en particular, agua de mar, extracto de Aloe vera y extracto de manzanilla, lo que las hace muy adecuadas para su uso en grupos de poblacion susceptibles, como pueden ser ninos, ancianos o embarazadas.The inventors have designed new decongestant compositions that have advantages in terms of effectiveness and comfort, while not presenting harmful side effects. These compositions comprise natural ingredients, in particular, sea water, Aloe vera extract and chamomile extract, which makes them very suitable for use in susceptible population groups, such as children, the elderly or pregnant women.

Asi pues, un primer aspecto de la invention se refiere a una composition acuosa que comprende: (i) de 0,5 a 3% en peso de NaCl; (ii) de 0,1 a 1% en peso de extracto de Aloe vera; y (iii) de 0,5 a 5% en peso de extracto de manzanilla, para su uso en la prevention y/o tratamiento de la congestion nasal. Este aspecto se puede reformular como el uso de una composicion que comprende: (i) de 0,5 a 3% en peso de NaCl; (ii) de 0,1 a 1% en peso de extracto de Aloe vera; y (iii) de 0,5 a 5% en peso de extracto de manzanilla, para la preparation de una medicamento para la prevencion y/oThus, a first aspect of the invention relates to an aqueous composition comprising: (i) from 0.5 to 3% by weight of NaCl; (ii) from 0.1 to 1% by weight of Aloe vera extract; and (iii) from 0.5 to 5% by weight of chamomile extract, for use in the prevention and / or treatment of nasal congestion. This aspect can be reformulated as the use of a composition comprising: (i) from 0.5 to 3% by weight of NaCl; (ii) from 0.1 to 1% by weight of Aloe vera extract; and (iii) from 0.5 to 5% by weight of chamomile extract, for the preparation of a medicine for prevention and / or

55

1010

15fifteen

20twenty

2525

3030

3535

tratamiento de la congestion nasal. La invention tambien se refiere a un metodo para la prevention y/o tratamiento de la congestion nasal que comprende la administration de una composition acuosa que comprende: (i) de 0,5 a 3% en peso de NaCl; (ii) de 0,1 a 1% en peso de extracto de Aloe vera; y (iii) de 0,5 a 5% en peso de extracto de manzanilla.Treatment of nasal congestion. The invention also relates to a method for the prevention and / or treatment of nasal congestion comprising the administration of an aqueous composition comprising: (i) from 0.5 to 3% by weight of NaCl; (ii) from 0.1 to 1% by weight of Aloe vera extract; and (iii) 0.5 to 5% by weight of chamomile extract.

Las concentraciones de los ingredientes de las composiciones segun la invencion se refieren siempre a porcentajes en peso sobre el peso total de la composicion acuosa (es decir, % peso, que tambien se expresa como % p/p).The concentrations of the ingredients of the compositions according to the invention always refer to percentages by weight over the total weight of the aqueous composition (ie,% weight, which is also expressed as% w / w).

En conjunto, los componentes (NaCl, extracto de Aloe vera y extracto de manzanilla) de la composicion disenada por los inventores proporciona una mayor efecto descongestivo a la vez que constituye un medio ideal para la limpieza e higiene nasal. En una realization particular la composicion descongestiva de acuerdo con la invencion es, ademas, adecuada para lavado nasal. El lavado nasal (o irrigation nasal), es la practica higienica personal en la que la cavidad nasal se lava para eliminar la suciedad y el exceso de mucosidad de nariz y senos paranasales. La irrigacion nasal en un sentido mas amplio tambien puede referirse a la utilization de un spray nasal salino o nebulizadores para humedecer las membranas mucosas y ejercer un efecto descongestivo y de lavado. El lavado (o irrigacion) nasal es muy importante para aliviar las molestias de la congestion y tambien para prevenir la congestion, ya que se eliminan de las fosas nasales residuos alergenos, infecciosos o irritantes que pueden causarla. Por tanto la composicion de acuerdo con la invencion es tambien util para higiene nasal. La composicion de acuerdo con la invencion es tambien util para irrigacion nasal.Together, the components (NaCl, Aloe vera extract and chamomile extract) of the composition designed by the inventors provide a greater decongestant effect while constituting an ideal means for nasal cleaning and hygiene. In a particular embodiment the decongestant composition according to the invention is also suitable for nasal lavage. Nasal lavage (or nasal irrigation), is the personal hygienic practice in which the nasal cavity is washed to remove dirt and excess mucus from the nose and sinuses. Nasal irrigation in a broader sense may also refer to the use of a saline nasal spray or nebulizers to moisten the mucous membranes and exert a decongestant and washing effect. Nasal lavage (or irrigation) is very important to relieve the discomfort of congestion and also to prevent congestion, since allergen, infectious or irritating residues that can cause it are removed from the nostrils. Therefore the composition according to the invention is also useful for nasal hygiene. The composition according to the invention is also useful for nasal irrigation.

Para ambos usos (descongestion y lavado o irrigacion nasal), la composicion segun la invencion presenta la ventaja de que proporciona un efecto hidratante y su aplicacion resulta mas agradable para el usuario. Ademas, la composicion, a partir de elementos puramente naturales presenta un elevado nivel de seguridad, sin efectos adversos, es respetuosa con el medio ambiente y adecuada para su uso en pacientes de riesgo como embarazadas, ninos o ancianos. Todo lo anterior permite tambien que la composicion segun la invencion pueda ser utilizada durante periodos mas prolongados en comparacion con otras composiciones conocidas en el estado de la tecnica sin general incomodidad, efecto rebote o conductas adictivas. Adicionalmente, lasFor both uses (decongestion and nasal washing or irrigation), the composition according to the invention has the advantage that it provides a moisturizing effect and its application is more pleasant for the user. In addition, the composition, based on purely natural elements, has a high level of safety, without adverse effects, is environmentally friendly and suitable for use in risk patients such as pregnant women, children or the elderly. All the foregoing also allows the composition according to the invention to be used for longer periods compared to other compositions known in the state of the art without general discomfort, rebound effect or addictive behaviors. Additionally, the

55

1010

15fifteen

20twenty

2525

3030

3535

sinergias establecidas entre los componentes de la invencion proporcionan un mayor efecto descongestivo y mayor bienestar al usuario.Synergies established between the components of the invention provide a greater decongestant effect and greater well-being for the user.

En la presente solicitud el termino "extracto" se utiliza en el sentido convencional para referirse a preparaciones concentradas de compuestos obtenidos mediante la extraccion de los constituyentes activos de la fuente, por lo general una fuente botanica, con medios adecuados. Dichos extractos contienen uno o mas ingredientes activos y se pueden incorporar en composiciones farmaceuticas o cosmeticas en una variedad de formas, incluyendo un componente puro o semi-puro, un extracto solido o Kquido, o una materia vegetal solida.In the present application the term "extract" is used in the conventional sense to refer to concentrated preparations of compounds obtained by extracting the active constituents from the source, usually a botanical source, with suitable means. Such extracts contain one or more active ingredients and can be incorporated into pharmaceutical or cosmetic compositions in a variety of ways, including a pure or semi-pure component, a solid or liquid extract, or a solid plant material.

Por lo general, los extractos botanicos contienen, no solo uno, sino multiples componentes, muchos de ellos activos. A veces, el efecto beneficioso se deriva de la combination de muchos de estos componentes activos. En otros casos hay un componente particular que es el principal responsable de la mayor parte de la actividad.In general, botanical extracts contain not only one, but multiple components, many of them active. Sometimes, the beneficial effect is derived from the combination of many of these active components. In other cases there is a particular component that is primarily responsible for most of the activity.

El termino “extracto” como se usa aqu tambien incluye extractos "sinteticos", es decir, varias combinaciones de componentes y / o componentes conocidos que se combinan para imitar sustancialmente la composition y / o la actividad de un extracto botanico de origen natural. Los extractos sinteticos tendran dos o mas, tres o mas, o cuatro o mas ingredientes activos en comun con la de la fuente natural. Los extractos naturales o sinteticos que estan enriquecidas en uno o varios componentes tambien se consideran parte de la presente invencion.The term "extract" as used herein also includes "synthetic" extracts, that is, several combinations of known components and / or components that combine to substantially mimic the composition and / or activity of a botanical extract of natural origin. Synthetic extracts will have two or more, three or more, or four or more active ingredients in common with that of the natural source. Natural or synthetic extracts that are enriched in one or more components are also considered part of the present invention.

El Aloe vera (tambien conocido como sabila, aloe de Barbados o aloe de Curazao, entre otros) es una planta suculenta que procede de sitios calurosos y deserticos, si bien se ha adaptado a una gran variedad de climas templados. Lo mas utilizado son las hojas, cada una compuesta por tres capas. La capa interna es un gel transparente que contiene una elevada cantidad de agua y compuestos activos como polisacaridos glucosidos, enzimas y minerales que son responsables de muchas de las propiedades de esta planta. La capa intermedia o latex es una savia amarilla amarga que contiene antraquinonas y glucosidos de efecto laxante. La capa externa gruesa, llamada corteza, tiene la funcion de protection y smtesis de carbohidratos y protemas. En general, las propiedades curativas del Aloe vera son conocidas desde antiguo y su usoAloe vera (also known as sabila, Barbados aloe or Curacao aloe, among others) is a succulent plant that comes from hot and desert sites, although it has adapted to a wide variety of temperate climates. The most used are the leaves, each composed of three layers. The inner layer is a transparent gel that contains a high amount of water and active compounds such as polysaccharides glucosides, enzymes and minerals that are responsible for many of the properties of this plant. The intermediate layer or latex is a bitter yellow sap that contains anthraquinones and laxative glucosides. The thick outer layer, called the cortex, has the function of protection and synthesis of carbohydrates and proteins. In general, the healing properties of Aloe vera are known since ancient times and their use

55

1010

15fifteen

20twenty

2525

3030

en composiciones topicas es habitual por su efecto antipruritico, cicatrizante, antiseptico, antioxidante, antiinflamatorio e hidratante. Sin embargo, su uso en composiciones anticongestivas y de higiene nasal no se ha descrito hasta la fecha.in topical compositions it is common for its antipruritic, healing, antiseptic, antioxidant, anti-inflammatory and moisturizing effect. However, its use in contraceptive and nasal hygiene compositions has not been described to date.

El extracto de Aloe vera es el extracto obtenido de las hojas de esta planta. Los procedimientos para obtener dicho extracto son conocidos en el estado de la tecnica. Los procesos adaptados a la industria farmaceutica, cosmetica y alimentaria eliminan los componentes irritantes que pueden contener las hojas de Aloe vera. Estos extractos pueden derivar del gel de Aloe vera, del latex, o de ambos. Las composiciones de acuerdo con la presente invencion pueden contener extracto de Aloe vera que contiene los componentes del gel, del latex o de ambos, pero preferentemente el extracto deriva del gel y contiene una elevada proporcion de polisacaridos. Cualquiera de las variedades de extracto de Aloe vera son facilmente adquiribles a traves de proveedores comerciales.Aloe vera extract is the extract obtained from the leaves of this plant. The procedures for obtaining said extract are known in the state of the art. The processes adapted to the pharmaceutical, cosmetic and food industry eliminate the irritating components that can be contained in Aloe vera leaves. These extracts may be derived from Aloe Vera gel, latex, or both. The compositions according to the present invention may contain Aloe Vera extract containing the components of the gel, latex or both, but preferably the extract is derived from the gel and contains a high proportion of polysaccharides. Any of the varieties of Aloe vera extract are easily available through commercial suppliers.

El extracto puro de gel de Aloe vera consiste en aproximadamente un 95% de agua y 5% de componentes activos. Los polisacaridos mucilaginosos son los principios activos responsables de la actividad biologica del gel de Aloe vera y entre ellos el acemanan es el mas relevante. Los restantes solidos que componen el gel de Aloe vera, y que tambien pueden contribuir a su actividad terapeutica, son sales organicas y acidos (glutamico, malico, salicflico, dtrico, lactato magnesico, oxalato calcico), enzimas (celulasa, carboxipeptidasa, bradikininasa, catalasa, amilasa, oxidasa, tirosinasa), taninos, esteroles, trigliceridos, aminoacidos (lisina, histidina, glutamina, arginina, acido aspartico, asparagina, treonina, serina, acido glutamico, glicina, alanina, valina, metionina, isoleucina, leucina, tirosina, fenilalanina y triptofano), RNA y trazas de alcaloides, de vitaminas (betacaroteno, B1, B2, B3, B6, C, E, colina, acido folico) y de minerales (aluminio, boro, bario, calcio, cromo, cobre, hierro, potasio, magnesio, sodio, fosforo, estroncio, silicio). El extracto puro del gel de Aloe vera puede ser concentrado y filtrado para eliminar el agua e incrementar la proporcion de agentes activos. El extracto de Aloe vera que se usa en las composiciones de acuerdo con la presente invencion es preferentemente un gel liquido sustancialmente puro (>95% de gel puro de aloe vera). Estos extractos de gel liquido pueden contener un extracto seco de aloe entre el 1 y el 5 %.The pure Aloe Vera gel extract consists of approximately 95% water and 5% active components. Mucilaginous polysaccharides are the active ingredients responsible for the biological activity of Aloe Vera gel and among them, acemanan is the most relevant. The remaining solids that make up the Aloe vera gel, and which can also contribute to its therapeutic activity, are organic salts and acids (glutamic, malico, salicylic, dtrico, magnesium lactate, calcium oxalate), enzymes (cellulase, carboxypeptidase, bradykininase, catalase, amylase, oxidase, tyrosinase), tannins, sterols, triglycerides, amino acids (lysine, histidine, glutamine, arginine, aspartic acid, asparagine, threonine, serine, glutamic acid, glycine, alanine, valine, methionine, isoleucine, leucine, leucine , phenylalanine and tryptophan), RNA and traces of alkaloids, of vitamins (beta-carotene, B1, B2, B3, B6, C, E, choline, folic acid) and minerals (aluminum, boron, barium, calcium, chromium, copper, iron, potassium, magnesium, sodium, phosphorus, strontium, silicon). The pure extract of Aloe Vera gel can be concentrated and filtered to remove water and increase the proportion of active agents. The Aloe vera extract used in the compositions according to the present invention is preferably a substantially pure liquid gel (> 95% pure aloe vera gel). These liquid gel extracts may contain a dry extract of aloe between 1 and 5%.

55

1010

15fifteen

20twenty

2525

3030

3535

La manzanilla o camomila es el nombre comun de varias plantas parecidas a las margaritas de la familia Asteraceae que se utilizan normalmente para hacer infusion de hierbas para servir a varios con fines medicinales. Compuestos activos relevantes presentes en la manzanilla incluyen apigenina y alfa-bisabolol. Tambien contiene sesquiterpenos, terpenoides, flavonoides, cumarinas tales como herniarina y umbeliferona, fenilpropanoides tales como el acido clorogenico y el acido cafeico, flavonas tales como apigenina y luteolina, flavanoles como la quercetina y rutina, y poliacetilenos.Chamomile or chamomile is the common name of several daisy-like plants of the Asteraceae family that are normally used to infuse herbs to serve various medicinal purposes. Relevant active compounds present in chamomile include apigenin and alpha-bisabolol. It also contains sesquiterpenes, terpenoids, flavonoids, coumarins such as herniarine and umbelliferone, phenylpropanoids such as chlorogenic acid and caffeic acid, flavones such as apigenin and luteolin, flavanols such as quercetin and rutin, and polyacetylenes.

El extracto de manzanilla se puede obtener por procedimientos conocidos en el estado de la tecnica o a traves de proveedores comerciales. El extracto es preferentemente extracto liquido. Estos extractos liquidos pueden contener un extracto seco de manzanilla entre el 1 y el 5 %.Chamomile extract can be obtained by procedures known in the state of the art or through commercial suppliers. The extract is preferably liquid extract. These liquid extracts may contain a dry chamomile extract between 1 and 5%.

El cloruro de sodio de la composition segun la invention puede provenir de diversas fuentes. Por ejemplo, se puede anadir: NaCl puro, agua de mar concentrada o agua purificada. Todas estas fuentes de NaCl son accesibles a traves de proveedores comerciales. En particular, el NaCl de la composicion de la invencion se puede proporcionar por la adicion a la composicion de agua de mar concentrada o por la adicion de agua de mar concentrada y agua purificada. En este caso la composicion contiene tambien otras sales y elementos que pueden contribuir al efecto descongestiva y/o a la adecuada higiene nasal.The sodium chloride of the composition according to the invention can come from various sources. For example, you can add: pure NaCl, concentrated sea water or purified water. All these sources of NaCl are accessible through commercial suppliers. In particular, the NaCl of the composition of the invention can be provided by the addition to the concentrated seawater composition or by the addition of concentrated seawater and purified water. In this case, the composition also contains other salts and elements that may contribute to the decongestant effect and / or proper nasal hygiene.

En una realization particular, la composicion segun la invencion comprende: (i) de 0,7 a 2.8% en peso de NaCl; (ii) de 0,3 a 0,8% en peso de extracto de Aloe vera; y (iii) de 0,8 a 3,5% en peso de extracto de manzanilla.In a particular embodiment, the composition according to the invention comprises: (i) from 0.7 to 2.8% by weight of NaCl; (ii) from 0.3 to 0.8% by weight of Aloe vera extract; and (iii) from 0.8 to 3.5% by weight of chamomile extract.

En algunas realizaciones particulares la composicion segun la invencion contiene tambien menta. En una realizacion la menta es menta piperita. La menta piperita es un hibrido esteril obtenido del cruce de la menta acuatica (mentha aquatica) y la hierbabuena (mentha spicata), que ocasionalmente se produce espontaneamente en las regiones templadas de Europa. Los componentes activos principales de la menta incluyen aceites esenciales (que contienen terpenos, principalmente mentol, neomentol, isomentol, neoisomentol, piperitoles, piperitenol, isopiperitenol) y flavonoides (diosmosido, diosmetosido, eriocitrosido, luteolol 7 rutosido,In some particular embodiments the composition according to the invention also contains mint. In one embodiment the mint is peppermint. Peppermint is a sterile hybrid obtained from the crossing of aquatic mint (mentha aquatica) and peppermint (mentha spicata), which occasionally occurs spontaneously in temperate regions of Europe. The main active components of peppermint include essential oils (containing terpenes, mainly menthol, neomenthol, isomenthol, neoisomenthol, piperitols, piperitenol, isopiperitenol) and flavonoids (diosmoside, diosmetoside, eriocytroside, luteolol 7 rutoside,

55

1010

15fifteen

20twenty

2525

3030

3535

hesperidosido). En una realization la composition contiene aroma de menta. El aroma de menta se puede obtener por procedimientos conocidos en el estado de la tecnica o a traves de proveedores comerciales. El aroma de menta es preferentemente un extracto liquido de menta. En una realizacion particular la concentration de aroma de menta es de 0,005 a 0,05 % en peso, o de 0,01 a 0,02% en peso, por ejemplo 0,015% en peso. En otra realizacion particular, la composicion contiene mentol o alguno de sus estereoisomeros en lugar del extracto o aroma de menta.hesperidoside). In a realization the composition contains mint aroma. Peppermint aroma can be obtained by procedures known in the state of the art or through commercial suppliers. The mint aroma is preferably a liquid mint extract. In a particular embodiment, the mint aroma concentration is 0.005 to 0.05% by weight, or 0.01 to 0.02% by weight, for example 0.015% by weight. In another particular embodiment, the composition contains menthol or some of its stereoisomers instead of the mint extract or aroma.

La composicion para la prevention o tratamiento de la congestion nasal segun la invention puede ser isotonica o hipertonica en funcion de la concentracion de NaCl que contenga. En una realizacion la composicion contiene de 2 a 3% en peso de NaCl y, por tanto, es hipertonica. En una realizacion particular la composicion contiene de 2,2 a 2,8% en peso de NaCl, mas particularmente 2.5% en peso de NaCl. Las composiciones hipertonicas de la invencion proporcionan la ventaja de ejercer un efecto descongestivo sin provocar efectos secundarios. En otra realizacion, la composicion contiene de 0,5 a 1,5% en peso de NaCl y es, por tanto, isotonica. En otra realizacion particular la composicion contiene de 0,7 a 1,1% en peso de NaCl, particularmente 0.9% en peso de NaCl. Las soluciones isotonicas de la invencion son efectivas en la prevencion de la congestion y son preferibles para su uso en bebes.The composition for the prevention or treatment of nasal congestion according to the invention may be isotonic or hypertonic depending on the concentration of NaCl it contains. In one embodiment the composition contains 2 to 3% by weight of NaCl and, therefore, is hypertonic. In a particular embodiment the composition contains from 2.2 to 2.8% by weight of NaCl, more particularly 2.5% by weight of NaCl. The hypertonic compositions of the invention provide the advantage of exerting a decongestant effect without causing side effects. In another embodiment, the composition contains 0.5 to 1.5% by weight of NaCl and is therefore isotonic. In another particular embodiment the composition contains 0.7 to 1.1% by weight of NaCl, particularly 0.9% by weight of NaCl. The isotonic solutions of the invention are effective in preventing congestion and are preferable for use in babies.

En una realizacion, la composicion de acuerdo con la invencion comprende (i) de 2 a 3% en peso de NaCl; (ii) de 0,3 a 0,8% en peso de extracto de Aloe vera; (iii) de 0,8 a 3,5% en peso de extracto de manzanilla y de 0,005 a 0,05 % de aroma de menta. En una realizacion particular, la composicion comprende (i) de 2,2 a 2,8% en peso de NaCl; (ii) de 0,4 a 0,6% en peso de extracto de Aloe vera; (iii) de 1,5 a 2,5% en peso de extracto de manzanilla y de 0,01 a 0,02 % de aroma de menta. En otra realizacion particular, la composicion comprende (i) 2,5% en peso de NaCl; (ii) 0,5% en peso de extracto de Aloe vera; (iii) 2% en peso de extracto de manzanilla y 0,015 % de aroma de menta.In one embodiment, the composition according to the invention comprises (i) from 2 to 3% by weight of NaCl; (ii) from 0.3 to 0.8% by weight of Aloe vera extract; (iii) from 0.8 to 3.5% by weight of chamomile extract and from 0.005 to 0.05% of peppermint aroma. In a particular embodiment, the composition comprises (i) from 2.2 to 2.8% by weight of NaCl; (ii) from 0.4 to 0.6% by weight of Aloe vera extract; (iii) from 1.5 to 2.5% by weight of chamomile extract and from 0.01 to 0.02% of peppermint aroma. In another particular embodiment, the composition comprises (i) 2.5% by weight of NaCl; (ii) 0.5% by weight of Aloe vera extract; (iii) 2% by weight of chamomile extract and 0.015% of mint aroma.

En una realizacion, la composicion de acuerdo con la invencion comprende (i) de 0.5 a 1.5% en peso de NaCl; (ii) de 0,3 a 0,8% en peso de extracto de Aloe vera; (iii) de 0,8 a 3,5% en peso de extracto de manzanilla y de 0,005 a 0,05 % de aroma de menta. En una realizacion particular, la composicion comprende (i) de 0,7 a 1,1% en peso de NaCl; (ii) de 0,4 a 0,6% en peso de extracto de Aloe vera; (iii) de 1,5 a 2,5%In one embodiment, the composition according to the invention comprises (i) from 0.5 to 1.5% by weight of NaCl; (ii) from 0.3 to 0.8% by weight of Aloe vera extract; (iii) from 0.8 to 3.5% by weight of chamomile extract and from 0.005 to 0.05% of peppermint aroma. In a particular embodiment, the composition comprises (i) from 0.7 to 1.1% by weight of NaCl; (ii) from 0.4 to 0.6% by weight of Aloe vera extract; (iii) from 1.5 to 2.5%

55

1010

15fifteen

20twenty

2525

3030

3535

en peso de extracto de manzanilla y de 0,01 a 0,02 % de aroma de menta. En otra realization particular, la composition comprende (i) 0,9% en peso de NaCI; (ii) 0,5% en peso de extracto de Aloe vera; (iii) 2% en peso de extracto de manzanilla y 0,015 % de aroma de menta.by weight of chamomile extract and 0.01 to 0.02% peppermint aroma. In another particular embodiment, the composition comprises (i) 0.9% by weight of NaCl; (ii) 0.5% by weight of Aloe vera extract; (iii) 2% by weight of chamomile extract and 0.015% of mint aroma.

Las composiciones arriba definidas de la presente invention pueden tener una consistencia liquida o espesa hasta semisolida. A manera de ejemplo, la composicion de acuerdo con la invencion puede presentarse como liquido, unguento, crema o gel para aplicarse a la nariz o como solution o dispersion para gotear o asperger en la nariz.The compositions defined above of the present invention may have a liquid or thick consistency until semi-solid. As an example, the composition according to the invention can be presented as a liquid, ointment, cream or gel to be applied to the nose or as a solution or dispersion for dripping or sprinkling in the nose.

Como vehiculo para formas de administration liquidas son adecuados, principalmente, sistemas acuosos. Como vehiculos para preparaciones espesas o semisolidas como, por ejemplo, unguentos, cremas o geles, son adecuados por ejemplo hidrocarburos de parafina, vaselina, productos de lanolina y otras materias de base, que elevan la viscosidad y que pueden usarse en farmacia; en el caso de geles hidrofilos, por ejemplo agua, glicerina o sorbitol, los cuales se gelifican con agentes de hinchamiento adecuados, como por ejemplo poli (acidos acrilicos) , derivados de celulosa, almidon o tragacanto. Principalmente en el caso de composiciones que contienen sal, el espesamiento se selecciona de tal modo que pueda impedirse en gran medida que fluya hacia la cavidad de la faringe.As a vehicle for liquid administration forms, mainly aqueous systems are suitable. As vehicles for thick or semi-solid preparations such as ointments, creams or gels, paraffin hydrocarbons, petrolatum, lanolin products and other base materials, which increase viscosity and can be used in pharmacy are suitable, for example; in the case of hydrophilic gels, for example water, glycerin or sorbitol, which gel with suitable swelling agents, such as poly (acrylic acids), cellulose derivatives, starch or tragacanth. Mainly in the case of compositions containing salt, the thickening is selected so that it can be largely prevented from flowing into the pharynx cavity.

La preparation de acuerdo con la invencion tambien puede contener, ademas de las sustancias activas y vehiculos otros coadyuvantes y/o aditivos farmaceuticos y compatibles con respecto a los principios activos, como por ejemplo: materiales de carga, disolventes, diluyentes, aglutinantes, humectantes, estabilizantes, colorantes, aromatizantes, conservantes, agentes propelentes, tampones, etc.The preparation according to the invention may also contain, in addition to the active substances and vehicles, other pharmaceutical adjuvants and / or additives compatible with the active ingredients, such as: fillers, solvents, diluents, binders, humectants, stabilizers, colorants, flavorings, preservatives, propellant agents, buffers, etc.

En una realizacion particular, la composicion de acuerdo con la invencion contiene propilenglicol. La concentration de propilenglicol en la composicion puede ser de 0,5 a 5 % en peso, o bien de 1 a 3 % en peso. En una realizacion particular la composicion segun la invencion comprende 2 % de propilenglicol.In a particular embodiment, the composition according to the invention contains propylene glycol. The concentration of propylene glycol in the composition can be from 0.5 to 5% by weight, or from 1 to 3% by weight. In a particular embodiment the composition according to the invention comprises 2% propylene glycol.

La presente invencion tambien proporciona una composicion acuosa para la prevention y/o tratamiento de la congestion nasal y/o para lavado nasal que seThe present invention also provides an aqueous composition for the prevention and / or treatment of nasal congestion and / or for nasal lavage that is

55

1010

15fifteen

20twenty

2525

3030

3535

caracteriza por la ausencia de excipientes. En una realization particular, por lo tanto, la invention proporciona una composition acuosa para la prevention y/o tratamiento de la congestion nasal y/o para lavado nasal que consiste en: (i) de 0,5 a 3% en peso de NaCl; (ii) de 0,1 a 1% en peso de extracto de Aloe vera, y (iii) de 0,5 a 5% en peso de extracto de manzanilla. En otra realizacion la invencion proporciona una composicion acuosa para la prevencion y/o tratamiento de la congestion nasal y/o para lavado nasal que consiste en: (i) de 0,5 a 3% en peso de NaCl; (ii) de 0,1 a 1% en peso de extracto de Aloe vera, (iii) de 0,5 a 5% en peso de extracto de manzanilla y aroma de menta o mentol. Cuando la composicion contiene aroma de menta, su concentration es de 0,005 a 0,05 % en peso.characterized by the absence of excipients. In a particular embodiment, therefore, the invention provides an aqueous composition for the prevention and / or treatment of nasal congestion and / or for nasal lavage consisting of: (i) from 0.5 to 3% by weight of NaCl ; (ii) from 0.1 to 1% by weight of Aloe vera extract, and (iii) from 0.5 to 5% by weight of chamomile extract. In another embodiment the invention provides an aqueous composition for the prevention and / or treatment of nasal congestion and / or for nasal lavage consisting of: (i) from 0.5 to 3% by weight of NaCl; (ii) from 0.1 to 1% by weight of Aloe vera extract, (iii) from 0.5 to 5% by weight of chamomile extract and mint or menthol aroma. When the composition contains mint aroma, its concentration is 0.005 to 0.05% by weight.

En una realizacion preferida la composicion de la invencion es para administration intranasal, preferentemente en forma de spray nasal o nebulizador nasal. La invencion tambien proporciona un spray nasal o nebulizador nasal que comprende la composicion segun la invencion.In a preferred embodiment the composition of the invention is for intranasal administration, preferably in the form of a nasal spray or nasal spray. The invention also provides a nasal spray or nasal nebulizer comprising the composition according to the invention.

La congestion nasal puede estar causada por diversas condiciones, bien procesos infecciosos, alergicos, polipos, etc. Entre estas condiciones destacan: resfriado (catarro) comun, gripe, infection sinusal, rinitis alergica u otras alergias, polipos y rinitis vasomotora. En una realizacion particular, las composiciones arriba descritas son para su uso en la prevencion y/o tratamiento de resfriado (catarro) comun, gripe, infeccion sinusal, rinitis alergica, polipos y rinitis vasomotora.Nasal congestion may be caused by various conditions, either infectious, allergic processes, polyps, etc. These include: common cold (cold), flu, sinus infection, allergic rhinitis or other allergies, polyps and vasomotor rhinitis. In a particular embodiment, the compositions described above are for use in the prevention and / or treatment of common cold (flu), flu, sinus infection, allergic rhinitis, polyps and vasomotor rhinitis.

A lo largo de la description y las reivindicaciones la palabra "comprende" y sus variantes no pretenden excluir otras caracteristicas tecnicas, aditivos, componentes o pasos. Ademas, la palabra “comprende” incluye el caso “consiste en”. Para los expertos en la materia, otros objetos, ventajas y caracteristicas de la invencion se desprenderan en parte de la descripcion y en parte de la practica de la invencion. Los siguientes ejemplos se proporcionan a modo de ilustracion, y no se pretende que sean limitativos de la presente invencion. Ademas, la presente invencion cubre todas las posibles combinaciones de realizaciones particulares y preferidas aqu indicadas.Throughout the description and claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or steps. In addition, the word "understand" includes the case "consists of". For those skilled in the art, other objects, advantages and characteristics of the invention will be derived partly from the description and partly from the practice of the invention. The following examples are provided by way of illustration, and are not intended to be limiting of the present invention. In addition, the present invention covers all possible combinations of particular and preferred embodiments indicated herein.

EJEMPLOSEXAMPLES

Composiciones descongestivas para spray nasal o nebulizador nasal.Decongestant compositions for nasal spray or nasal spray.

Se han formulado las siguientes composiciones:The following compositions have been formulated:

Tabla 1. Composiciones para spray nasalTable 1. Compositions for nasal spray

componente  component
Unidades (g) Unidades (g) % (p/p) del total  Units (g) Units (g)% (w / w) of the total

Agua de mar 1  Sea water 1
23,4375 93,75 78,125  23.4375 93.75 78,125

Agua purificada  Purified water
5,208 20,832 17,36  5,208 20,832 17.36

Extracto de manzanilla  Chamomile extract
0,6 2,4 2  0.6 2.4 2

Propilenglicol  Propylene glycol
0,6 2,4 2  0.6 2.4 2

Extracto de Aloe vera  Aloe Vera Extract
0,15 0,6 0,5  0.15 0.6 0.5

Aroma de menta  Mint Aroma
0,0045 0,018 0,015  0.0045 0.018 0.015

TOTAL  TOTAL
30,0 120,0 100  30.0 120.0 100

5 (1) La concentration de NaCl proporcionada por el agua de mar es 2,5% (solution5 (1) The concentration of NaCl provided by seawater is 2.5% (solution

hipertonica)hypertonic)

Las composiciones se administraron en forma de spray nasal a un panel de usuarios, siendo su aceptacion entre los usuarios mayor que productos similares disponibles en 10 el mercado.The compositions were administered in the form of a nasal spray to a panel of users, their acceptance among users being greater than similar products available in the market.

ExtractosExcerpts

Los extractos utilizados en la elaboration de las composiciones de la tabla 1 fueron los 15 siguientes:The extracts used in the elaboration of the compositions of table 1 were the following:

a) Extracto de Aloe vera. El extracto de aloe utilizado fue 71010 ALOVERIA® (n° CAS 902 760 000). Este extracto es un gel liquido transparente obtenido directamente de hojas frescas de la planta. Contiene un 99,6% de gel de Aloe vera Linn puro y 20 excipientes (benzoato sodico, acido ascorbico, bisulfito sodico y sorbato potasico. La tabla 2 contiene mas information sobre este extracto, incluyendo su composition (listado no exhaustivo).a) Aloe vera extract. The aloe extract used was 71010 ALOVERIA® (CAS No. 902 760 000). This extract is a transparent liquid gel obtained directly from fresh leaves of the plant. It contains 99.6% pure Aloe Vera gel and 20 excipients (sodium benzoate, ascorbic acid, sodium bisulfite and potassium sorbate. Table 2 contains more information on this extract, including its composition (non-exhaustive list).

Tabla 2. 71010 ALOVERIA®Table 2. 71010 ALOVERIA®

Extracto seco  Dry extract
1,5 -2,5 %  1.5 -2.5%

pH  pH
4,5 -5,5  4.5-5.5

Densidad  Density
0,980 -1,020 g/ml  0.980 -1.020 g / ml

Composition  Composition
Polisacaridos >0,2 g  Polysaccharides> 0.2 g

Acemanan >0,1 g  Acemanan> 0.1 g

Fibra cruda >0,05 g  Raw fiber> 0.05 g

Aminoacidos esenciales >35 ppm  Essential amino acids> 35 ppm

Protemas >0,18 g  Protemes> 0.18 g

grasas <0,12  fat <0.12

Antraquinonas (barbaloin) <2 ppm  Anthraquinones (barbaloin) <2 ppm

b) Extracto de manzanilla. El extracto de manzanilla utilizado fue obtenido de la empresa Genox Farma. Se trata de un extracto Kquido de flores de Matricaria chamomilla L obtenido por percolacion mediante mezcla de alcohol y agua. La tabla 3 5 contiene mas informacion sobre este extracto.b) Chamomile extract. The chamomile extract used was obtained from the company Genox Farma. It is a Kquido extract of flowers of Matricaria chamomilla L obtained by percolation by mixing alcohol and water. Table 3-5 contains more information about this extract.

Tabla 3. Extracto de manzanilla (Genox Farma)Table 3. Chamomile extract (Genox Farma)

Extracto seco  Dry extract
2,0-4,0 %  2.0-4.0%

pH  pH
4,0-7,0  4.0-7.0

Densidad  Density
0,980-0,995 g/ml  0.980-0.995 g / ml

alcohol  alcohol
23-27°  23-27 °

agua  Water
69-75%  69-75%

c) Aroma de menta. El aroma de menta utilizado fue obtenido de la empresa IFF 10 (AROMA MENTA LIQ SC397979 MP061). La tabla 4 contiene mas informacion sobre este producto.c) Mint aroma. The mint aroma used was obtained from the company IFF 10 (AROMA MENTA LIQ SC397979 MP061). Table 4 contains more information about this product.

Tabla 4. AROMA MENTA LIQ SC397979 MP061Table 4. AROMA MENTA LIQ SC397979 MP061

Consistencia  Consistency
liquida  liquid

Densidad  Density
0,890-0,910 g/ml  0.890-0.910 g / ml

indice de refraction ND20  refraction index ND20
1,450 -1,470  1,450 -1,470

Gravedad espedfica D25/25°C  Specific gravity D25 / 25 ° C
0,869 - 0,909  0.869 - 0.909

punto de inflamabilidad  Flash point
73°C  73 ° C

Claims (15)

55 1010 15fifteen 20twenty 2525 3030 REIVINDICACIONES 1. Uso de una composition acuosa que comprende:1. Use of an aqueous composition comprising: (i) de 0,5 a 3% en peso de NaCI(i) 0.5 to 3% by weight of NaCl (ii) de 0,1 a 1% en peso de extracto de Aloe vera, y(ii) from 0.1 to 1% by weight of Aloe vera extract, and (iii) de 0,5 a 5% en peso de extracto de manzanilla(iii) 0.5 to 5% by weight of chamomile extract para la preparation de un medicamento para la prevention y/o tratamiento de la congestion nasal.for the preparation of a medication for the prevention and / or treatment of nasal congestion. 2. Uso segun la reivindicacion 1, donde la composicion ademas es para lavado nasal.2. Use according to claim 1, wherein the composition is also for nasal lavage. 3. Uso segun cualquiera de las reivindicaciones 1-2, donde los extractos son extractos Kquidos.3. Use according to any of claims 1-2, wherein the extracts are liquid extracts. 4. Uso segun cualquiera de las reivindicaciones 1-3, donde la composicion ademas comprende menta.4. Use according to any of claims 1-3, wherein the composition further comprises mint. 5. Uso segun la reivindicacion 4, donde la composicion contiene aroma de menta a una concentration de 0,005 a 0,05 % en peso.5. Use according to claim 4, wherein the composition contains mint aroma at a concentration of 0.005 to 0.05% by weight. 6. Uso segun cualquiera de las reivindicaciones 1-5, donde la composicion comprende:6. Use according to any of claims 1-5, wherein the composition comprises: (i) de 0,7 a 2,8% en peso de NaCl(i) from 0.7 to 2.8% by weight of NaCl (ii) de 0,3 a 0,8% en peso de extracto de Aloe vera, y(ii) from 0.3 to 0.8% by weight of Aloe vera extract, and (iii) de 0,8 a 3,5% en peso de extracto de manzanilla.(iii) from 0.8 to 3.5% by weight of chamomile extract. 7. Uso segun cualquiera de las reivindicaciones 1-6, donde la composicion contiene de 0,7 a 1,1% en peso de NaCl.7. Use according to any of claims 1-6, wherein the composition contains from 0.7 to 1.1% by weight of NaCl. 8. Uso segun cualquiera de las reivindicaciones 1-6, donde la composicion contiene de 2,2 a 2,8% en peso de NaCl.8. Use according to any of claims 1-6, wherein the composition contains from 2.2 to 2.8% by weight of NaCl. 9. Uso segun la reivindicacion 8, donde la composicion ademas comprende de 0,01 a 0,02% en peso de aroma de menta.9. Use according to claim 8, wherein the composition also comprises 0.01 to 0.02% by weight of mint aroma. 10. Uso segun cualquiera de las reivindicaciones 1-9, donde la composicion se caracteriza por la ausencia de excipientes.10. Use according to any of claims 1-9, wherein the composition is characterized by the absence of excipients. 11. Uso segun cualquiera de las reivindicaciones 1-9, donde la composicion tambien 5 comprende excipientes y/o vehiculos farmaceuticamente aceptables.11. Use according to any of claims 1-9, wherein the composition also comprises pharmaceutically acceptable excipients and / or vehicles. 12. Uso segun la reivindicacion 11, donde la composicion contiene propilenglicol.12. Use according to claim 11, wherein the composition contains propylene glycol. 13. Uso segun la reivindicacion 12, donde la concentration de propilenglicol es de 0,5 10 a 5 % en peso.13. Use according to claim 12, wherein the concentration of propylene glycol is 0.5 to 5% by weight. 14. Uso segun cualquiera de las reivindicaciones 1-13, donde la composicion se administra como spray nasal o nebulizador nasal.14. Use according to any of claims 1-13, wherein the composition is administered as a nasal spray or nasal spray. 15 15. Uso segun cualquiera de las reivindicaciones 1-14, en el cual la congestion nasal15. Use according to any of claims 1-14, wherein the nasal congestion esta causada por resfriado (catarro) comun, gripe, infection sinusal, rinitis alergica, polipos o rinitis vasomotora.It is caused by a common cold (cold), flu, sinus infection, allergic rhinitis, polyps or vasomotor rhinitis. 16. Spray nasal o nebulizador nasal que comprende la composicion tal como se define 20 en cualquiera de las reivindicaciones 1, 3-14.16. Nasal spray or nasal nebulizer comprising the composition as defined in any of claims 1, 3-14.
ES201531879A 2015-12-22 2015-12-22 Use of an aqueous composition comprising NaCl, Aloe and chamomile for the treatment and / or prevention of nasal congestion Active ES2631137B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201531879A ES2631137B1 (en) 2015-12-22 2015-12-22 Use of an aqueous composition comprising NaCl, Aloe and chamomile for the treatment and / or prevention of nasal congestion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201531879A ES2631137B1 (en) 2015-12-22 2015-12-22 Use of an aqueous composition comprising NaCl, Aloe and chamomile for the treatment and / or prevention of nasal congestion

Publications (2)

Publication Number Publication Date
ES2631137A1 true ES2631137A1 (en) 2017-08-28
ES2631137B1 ES2631137B1 (en) 2018-09-11

Family

ID=59656255

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201531879A Active ES2631137B1 (en) 2015-12-22 2015-12-22 Use of an aqueous composition comprising NaCl, Aloe and chamomile for the treatment and / or prevention of nasal congestion

Country Status (1)

Country Link
ES (1) ES2631137B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2780378C1 (en) * 2019-02-15 2022-09-22 Феррер Медикал Инновейшнз, Ллс Nasal spray compositions and associated treatment methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804211A (en) * 1996-06-05 1998-09-08 Health Pharm Usa, Inc. Composition and method for suppressing or eliminating snoring
WO2010078419A2 (en) * 2008-12-31 2010-07-08 Bzmi, Llc Herbal-based nasal solution and method of use thereof
CN104274633A (en) * 2014-01-13 2015-01-14 北京德默高科医药技术有限公司 Composition for cleaning and protecting nose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804211A (en) * 1996-06-05 1998-09-08 Health Pharm Usa, Inc. Composition and method for suppressing or eliminating snoring
WO2010078419A2 (en) * 2008-12-31 2010-07-08 Bzmi, Llc Herbal-based nasal solution and method of use thereof
CN104274633A (en) * 2014-01-13 2015-01-14 北京德默高科医药技术有限公司 Composition for cleaning and protecting nose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PharmaLink "Ferias y Eventos", [recuperado el 23.06.2016]. Recuperado de Internet: http://www.pharmalink.es/es/news *
Sprays agua de mar-Spray nasal hipertónico con Aloe vera y manzanilla, [recuperado el 23.06.2016]. Recuperado de Internet: http://www.pharmalink.es/es/products/Sea-Water-Range/hipertonic-nasal-spray-with-aloe-vera-and-camimilla-120ml-6 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2780378C1 (en) * 2019-02-15 2022-09-22 Феррер Медикал Инновейшнз, Ллс Nasal spray compositions and associated treatment methods

Also Published As

Publication number Publication date
ES2631137B1 (en) 2018-09-11

Similar Documents

Publication Publication Date Title
ES2368974T3 (en) PREPARATION CONTAINING OSMOLITES FOR USE IN CASE OF DRY MUCOUS MEMBRANES.
ES2949139T3 (en) Composition that eliminates nasal congestion and has antiviral activity
US20100303935A1 (en) Medicinal Composition
ES2730088T3 (en) Formulations for the treatment of disorders of the mouth, throat and respiratory tract
ES2606141T3 (en) Compositions for the treatment of peripheral ulcers of various origins
CA2933787A1 (en) Composition for use in the treatment of persistent cough
BRPI1106762A2 (en) POLYMERIC COMPOSITION CONTAINING NATURAL BIOACTIVES APPLICABLE IN PHARMACEUTICAL AND COSMETIC FORMULATIONS
US20100322961A1 (en) Intranasal Drug Delivery System
ES2588741T3 (en) Process for the preparation of alcohol-free compositions on a plant basis, as well as compositions prepared in this way and their use
ES2743210T3 (en) Plant-based composition for use in the treatment of cough
Ambareen et al. Go green-keep the root canal clean
TR201802779T4 (en) Herbal formulations.
ES2631137B1 (en) Use of an aqueous composition comprising NaCl, Aloe and chamomile for the treatment and / or prevention of nasal congestion
US20170020946A1 (en) Analgesic compositions and methods of use
CN1589852A (en) External use nose drop agent for treating common cold and its preparation method
JP2012193159A (en) Nasal spray
ES2809463T3 (en) Composition of natural anti-flu antioxidants
Armutcu et al. Herbal Remedies for Respiratory Tract Infections
ES2705692T3 (en) Topical nasal compositions containing xyloglucans for use as decongestants
CN104524519A (en) Special handkerchief paper suitable for patient suffering cold in the bud
CN1263470C (en) External use nose drops agent for treating common cold and its preparation method
DK181405B1 (en) Gel for Intranasal Application, its Provision and Use
US11878032B2 (en) Aqueous saline composition, process for the production of same, and use of same
ES2382845B2 (en) IMPROVEMENTS INTRODUCED IN THE MAIN PATENT P200400524 FOR &#34;NATURAL LIQUID COMPOSITION AGAINST INFECTIONS&#34;.
ITMI20092343A1 (en) BACTERICIDAL AND VIRUCID COMPOSITION FOR THE ORAL CABLE

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2631137

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20180911